Latest News | Windlas Biotech Dehradun Plant Gets No Critical Observation in EU Inspection
Get latest articles and stories on Latest News at LatestLY. Windlas Biotech Ltd on Thursday said it has concluded European Union good manufacturing practice inspection carried out by the National Institute of Pharmacy and Nutrition, Hungary, for its Plant-IV at Dehradun with zero critical observations.
New Delhi, Apr 14 (PTI) Windlas Biotech Ltd on Thursday said it has concluded European Union good manufacturing practice inspection carried out by the National Institute of Pharmacy and Nutrition, Hungary, for its Plant-IV at Dehradun with zero critical observations.
In a regulatory filing, the company, which is a pharmaceutical formulations contract development and manufacturing organisation, said the inspection took place from April 11-13, 2022.
Also Read | Redmi 10A To Be Launched in India on April 20; Expected Prices, Features & Specifications.
"Based on our preliminary discussion with the agency in the sum-up meeting, we estimate zero critical observations and deficiencies, including no observations related to Data Integrity issue," Windlas Biotech Managing Director Hitesh Windlass said.
The Inspection report will be issued by the agency within 30 days of completion of inspection, he added.
Also Read | iQoo Z6 Pro 5G India Launch Set for April 27, 2022.
"The successful completion of this inspection will enable the company to explore new geographical expansion avenues and reinforce presence in the entire European market," Windlass said.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)